Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 10,535 matching trials from the live ClinicalTrials.gov search.
Filters: Active, not recruiting Clear all
Active, not recruiting Not applicable Interventional

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

NCT01872975
View directory record Official record
Conditions
Stage IB Breast Cancer, Stage II Breast Cancer
Interventions
regional nodal XRT, chestwall XRT, WBI
Radiation
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
1,636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
489
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 356 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional

Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)

NCT06311045
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
N-acetylcysteine (NAC), Placebo, Positive Airway Pressure (PAP) Therapy
Dietary Supplement · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional

Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)

NCT03838445
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
V-Wave Interatrial Shunt
Device
Lead sponsor
V-Wave Ltd
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional

The HOME Program for Individuals With Traumatic Brain Injury and Family Members

NCT05117619
View directory record Official record
Conditions
Brain Injuries, Traumatic
Interventions
HOME for Us, Attention-control condition
Behavioral
Lead sponsor
Villanova University
Other
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Villanova, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional

Osteopathic Manipulation Makes a Neuropsychological Difference

NCT04058431
View directory record Official record
Conditions
Cognitive Change, Musculoskeletal Pain
Interventions
Osteopathic Manipulative Treatment, Control- No Intervention
Other
Lead sponsor
Midwestern University
Other
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Downers Grove, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional

Transcranial Direct Current to Treat Epilepsy at Home

NCT04309812
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
transcranial direct current stimulation (tDCS)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effect of (TaVNS) on Anxiety and Brain Function in Distressed Health Care Workers

NCT05132881
View directory record Official record
Conditions
Anxiety, Distress, Emotional, Effects of Vibration, Healthy
Interventions
Neuvana 2.0 Transcutaneous Auricular Vagal Nerve Stimulation (TaVNS), Waitlist Control, Healthy Controls: Substudy Group III, Distressed Workers: Subgroup II
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 2 Interventional Results available

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

NCT03348631
View directory record Official record
Conditions
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma
Interventions
Computed Tomography, Magnetic Resonance Imaging, Tazemetostat
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
581
States / cities
Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 369 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting No phase listed Observational

Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma

NCT04055753
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Doxil, Doxorubicin
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 2 Interventional Results available

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

NCT04756401
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Carfilzomib, Daratumumab, Dexamethasone, Quality-of-Life Assessment, Selinexor
Drug · Biological · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Hackensack, New Jersey • Syracuse, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 2 Interventional

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

NCT01217931
View directory record Official record
Conditions
Kidney Cancer
Interventions
Pazopanib, Bevacizumab, Everolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional

Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management

NCT06420245
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Orion TM Amniotic Membrane Allograft, Standard of Care (SOC)
Device · Procedure
Lead sponsor
Legacy Medical Consultants
Industry
Eligibility
50 Years to 85 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Palm Springs, California • San Francisco, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 1 Interventional

Study of CG0070 After Transurethral Resection in Patients With IR NMIBC

NCT06253845
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
CG0070
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 1 Interventional

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

NCT04754945
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Bortezomib, Cyclophosphamide, Dexamethasone, Isatuximab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
Orange, California • Atlanta, Georgia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

CB1R in Synthetic Psychoactive Cannabinoids

NCT03539575
View directory record Official record
Conditions
Drug Dependence
Interventions
[11-C]OMAR
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional

Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12

NCT05454189
View directory record Official record
Conditions
Maintenance of Implanted Port Devices
Interventions
Reduced IPD Flush Schedule, Standard IPD Flush Schedule
Device
Lead sponsor
Essentia Health
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
17
States / cities
Albert Lea, Minnesota • Brainerd, Minnesota • Deer River, Minnesota + 13 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 1 Interventional

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

NCT05411497
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous MUC1-activated T-cells, Cyclophosphamide
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Phoenix, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional

Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection

NCT05879159
View directory record Official record
Conditions
Liver
Interventions
Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 2 Interventional

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

NCT03237780
View directory record Official record
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography with Contrast, Eribulin Mesylate
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
21
States / cities
Birmingham, Alabama • Buena Park, California • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Impact of a Novel Extended Depth of Focus Intraocular Lens on Visual and Lifestyle Enhancement

NCT04570579
View directory record Official record
Conditions
Cataract, Cataract Senile, Presbyopia
Interventions
Vivity Extended Depth of Focus Intraocular Lens
Device
Lead sponsor
Alanna Nattis, DO
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Babylon, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 2 Interventional

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis

NCT07065773
View directory record Official record
Conditions
Onychomycosis of Toenail
Interventions
Trichostatin A
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Fremont, California • Denver, Colorado • New Brighton, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 2 Interventional Results available

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

NCT03141359
View directory record Official record
Conditions
Lung Cancer Stage II, Lung Cancer Stage III, Non Small Cell Lung Cancer
Interventions
SBRT, Carboplatin, Paclitaxel, cis Platinum, Etoposide, IMRT, Durvalumab
Radiation · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Not applicable Interventional

Project 3: ACHIEVE- CHD

NCT05918380
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
PAL2, CINEMA
Behavioral · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 14, 2026, 10:57 PM EST
Active, not recruiting Phase 4 Interventional

Connective Tissue Matrix for Rotator Cuff Tendinopathy

NCT06160427
View directory record Official record
Conditions
Tendinopathy, Shoulder Pain, Rotator Cuff Tendinitis, Rotator Cuff Tendinosis
Interventions
CTM Boost, PRP
Biological
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania • Wexford, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Nov 14, 2026, 10:57 PM EST